Executive summary:
The current headline is one molecule is ~43% of revenue, its patents have expired, generics have landed in the US, and the partner has guided its own sales down ~11%. All true albeit partially but it describes PI as it was, not as it is being rebuilt. A read through the environmental filings, SEZ approvals the Technology Absorption annexures of the annual reports, the media briefs, interviews — and a different company appears: one converting a single-molecule dominated contract-manufacturing franchise into a multi-vertical fine-chemicals industrial platform, where agrochemical CSM is the cash engine rather than the whole business.
A brief history: PI began in 1946 in Udaipur as Mewar Oil & General Mills — an oil mill, not a chemicals company. It moved into agrochemicals through the 1960s–70s, then made the decision that defines it today: rather than compete as a generic molecule producer, it built a custom synthesis & manufacturing (CSM) business serving global innovators from the 1990s. That traded volume for chemistry depth, and it compounded — the Kumiai relationship alone drove ~19% CSM revenue CAGR over a decade, and PI now works with 20+ innovators (Kumiai, FMC, Syngenta, ADAMA, Sumitomo, Bayer, BASF, Kureha, Nissan Chemical, Corteva).
The asset base grew : Udaipur (1946 origin; today the R&D nerve centre — 4 R&D centres, 700+ scientists, 200+ PhDs, and a fully automated 1 MT/day flow pilot plant) → Panoli, GIDC Ankleshwar (technical + formulation; materially expanded by the Isagro Asia acquisition completed Dec 2019, which added a site plus 18 domestic and 91 export registrations) → Jambusar, in the Sterling SEZ, Bharuch — the growth engine, built from an original 7,000 MTPA environmental clearance in 2011 and now home to the Flow MPP (commissioned FY26) and a phosgene MPP under construction. The July 2020 QIP placement document disclosed 17,362 MT of technical capacity. The current environmental clearances are far larger: the two Jambusar units are cleared at 43,240 and 44,240 MTPA respectively. FY26 AR describes 16 multi-product plants across 150+ acres add to these the three overseas legs added since 2023 — Lodi (Italy, EU-GMP API), St. Louis / Seattle (PI AgSciences biologicals) and **Hyderabad / Alabama (pharma discovery).
**
The capability stack:
Six businesses
• Agchem CSM — the cash engine (~80% of revenue), still pyroxa-heavy but with 15–20+ new molecules commercialised in three years
• Agchem domestic — brand-led, now getting genuinely novel chemistry (dicloromezotiaz)
• Biologicals (PI AgSciences) — peptide/protein plant-immunity platform; small, differentiated, very high EBITDA, loss-making
• Agchem NCE (Pioxaniliprole) — India’s first indigenously discovered insecticide; own IP to ~2039
• Pharma (PI Health Sciences) — CRDMO across India + EU-GMP Italy; mid-turnaround
• Electronic & performance chemicals — a brand-new 1,000 MTPA cleared group, commercial plant running, >50% of new CSM enquiries as per company.
Before we jump into each segment the these in one line: The thesis in one line
PI spent FY22–FY26 converting pyroxasulfone cash into optionality across five new verticals, and is now at the point where those verticals must start showing revenue while the core molecule decays. FY26–FY27 is the proving window and the management has guided for growth this year. Balance sheet buys the time: debt-free, net cash ~₹35bn, FY26 capex ₹11,508mn falling to guided ₹500–600 cr in FY27 — the heavy build is largely done.
• PI Integrated Annual Report FY2024-25
• PI Annual Report FY2021-22 (Annexure ‘E’ — azide chemistry, electronic chemicals foray)
• Environmental Clearance, Jambusar SPM-29/2, granted 17 Sep 2025 (IA/GJ/IND3/539466/2025)
• Environmental Clearance, Jambusar SPM-28 + SPM-29/1, granted 30 Jan 2026 (IA/GJ/IND3/539236/2025)
• Q1 FY27 earnings call transcript, 12 Aug 2026
• Saumendu Mandal, VP & Design and Engineering Head, PI Industries — LinkedIn profile
